ClinicalTrials.gg
CompletedNCT06406517Updated Nov 3, 2026

Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics

A Phase 3 interventional study of Gadopiclenol and Gadobenate dimeglumine in Congenital Heart Disease, sponsored by University of California, San Diego. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of California, San Diego · Phase 3, Interventional, and Other

How we know

Updated Nov 3, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 356 studies in Heart Defects, Congenital with a site in United States — 67 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.

Enrollment
34th of 184
161 · median 48
Started
2024
with 15 others
Phase 3
19 of 356
2 open now
Registered
320th of 356
by date

Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 34th largest by enrollment of the 184 interventional ones that give a count, is one of 16 that started in 2024, is one of 19 in phase 3, and was the 320th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

67 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:

62 more — sign in →

All 67 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 356 studies in Heart Defects, Congenital with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn how well and at what doses gadopiclenol, a new intravenous (IV) contrast agent used for MRI, works to produce high-quality MRI images of the heart, in patients with a history of congenital heart disease, when compared to gadobenate dimeglumine, the IV contrast agent that is normally used at our institution for heart (cardiac) MRI. The main questions it aims to answer are:

  • Does using gadopiclenol result in similar or superior image quality, similar signal-to-noise ratio (SNR), and similar flow measurements with 4-dimensional (4D) flow cardiac MRI when compared to gadobenate dimeglumine?
  • At what dose(s) does gadopiclenol result in similar image quality (using the above metrics) for cardiac MRI when compared to gadobenate dimeglumine?

Researchers will compare cardiac MRI images obtained after administration of gadopiclenol to cardiac MRI images obtained after administration of gadobenate dimeglumine (called the standard of care treatment) to see if the images are of similar or superior quality.

Participants will:

  • Be randomized to receive either gadopiclenol at one of three different doses or gadobenate dimeglumine before their congenital heart cardiac MRI
  • Undergo their congenital heart cardiac MRI as they would during the course of normal clinical care.
Read the detailed description

At the University of California San Diego (UCSD), the investigators have developed a premier advanced clinical cardiovascular imaging program, which is a critical component of our Adult Congenital Heart Association (ACHA)-accredited adult congenital heart program. Central to these programs is 4D Flow MRI, which enables hemodynamic assessment of patients with repaired and unrepaired congenital heart disease. Adults with congenital heart disease require routine MRI for surveillance and management of complications of disease and repairs, and 4D Flow allows us to reliably perform these exams efficiently and accurately. Multiple works by our group, and confirmed by others, have highlighted the value of 4D Flow MRI for evaluating this patient population, and for vascular imaging applications beyond the heart.

Gadopiclenol is a recently FDA-approved intravenous, extracellular gadolinium contrast agent indicated for use in MRI. Though it has been shown to be effective in detection of central nervous system (CNS) lesions and of lesions outside the CNS, its performance in cardiovascular imaging is unknown, particularly in cardiac MRI performed for evaluation of adult congenital heart disease. The investigators therefore seek to evaluate whether use of gadopiclenol results in superior image quality compared to, and therefore may be used in place of, gadobenate dimeglumine, our current standard of care in 4D Flow MRI and MR Angiography (MRA).

In our current clinical practice, like many others, gadobenate dimeglumine at 0.3 mL/kg (0.15 mmol/kg) is our standard of care for vascular enhancement and cardiac MRI, favored due to its long blood pool residence time, which parallels the longer acquisition time for 4D Flow MRI (\~10 minutes), and its strong T1 shortening properties. Gadopiclenol, with its stronger T1 shortening properties and similar pharmacokinetics, may achieve similar effects but as a macrocyclic agent is a more stable gadolinium agent, and theoretically may have a better retention profile than older linear agents due to its lower approved dose. The investigators therefore seek to determine whether gadopiclenol may be used in place of gadobenate dimeglumine for contrast-enhanced 4D Flow MRI and MRA. Since the optimal dose of gadopiclenol for this purpose is unknown, the investigators will assess the relative performance of gadopiclenol across a dose range.

Standard dosing for gadopiclenol for CNS and abdominal imaging in adult and pediatric patients is 0.05 mmol/kg actual body weight (equivalent to 0.1 mL/kg). However, its safety has been evaluated at doses ranging from 0.025 mmol/kg to 0.3 mmol/kg. The investigators therefore plan to assess the signal to noise ratio and image quality of patients undergoing cardiac MRI using gadopiclenol at three doses (0.075 mmol/kg, 0.10 mmol/kg, 0.15 mmol/kg) against our standard of care (gadobenate dimeglumine at 0.3 mL/kg (0.15 mmol/kg)). The investigators hypothesize that gadopiclenol at each dose will be non-inferior to gadobenate dimeglumine, achieving similar qualitative image quality, similar SNR, and similar standard deviation amongst flow measurements with 4D Flow MRI. There is a strong possibility that gadopiclenol at an equimolar gadolinium dose to gadobenate dimeglumine will provide superior qualitative image quality and superior SNR in contrast-enhanced MRA and reduce standard deviation amongst flow measurements with 4D Flow MRI.

03

Conditions studied

  • Congenital Heart Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥ 18 years old)
  • History of congenital heart disease and scheduled to undergo standard of care cardiac MRI and chest MRA as part of routine clinical care
  • English is patient's primary spoken language

Exclusion criteria

Exclusion Criteria:

  • Pediatric patients
  • Pregnant patients
  • Patients with ongoing acute kidney injury (AKI) or severe, chronic kidney disease ( \< 30 mL/min/1.73m2)
  • History of reaction to gadolinium based contrast agent
  • English is not the patient's primary spoken language
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
161 participants (actual)

Study arms

  • Active comparator
    Gadobenate dimeglumine 0.15 mmol/kg (standard of care)

    Drug: Gadobenate dimeglumine

  • Experimental
    Gadopiclenol 0.075 mmol/kg

    Drug: Gadopiclenol

  • Experimental
    Gadopiclenol 0.10 mmol/kg

    Drug: Gadopiclenol

  • Experimental
    Gadopiclenol 0.15 mmol/kg

    Drug: Gadopiclenol

Interventions

  • Gadopiclenol is an FDA-approved gadolinium-based contrast agent (GBCA) for neurological and abdominal contrast-enhanced MRI. Participants will receive this contrast agent at one of three different doses prior to undergoing a congenital heart cardiac MRI/MRA. This contrast agent will be compared to gadobenate dimeglumine, the standard-of-care.

    Also known as: Vueway

  • DrugGadobenic acidStudies of Gadobenic acidGadobenic acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Gadobenate dimeglumine is an FDA-approved GBCA that is used in standard clinical practice at UCSD for contrast-enhanced MRI/MRA studies, including cardiac MRI/MRA. This contrast agent is the standard of care to which gadopiclenol will be compared.

    Also known as: Multihance

06

What researchers measure

Primary outcomes

  1. Image Quality

    Images will be qualitatively scored by three attending radiologists for quality of contrast enhancement on a 5-point likert Scale

    Time frame: Image Quality will be assessed on a rolling basis during the study by all radiologists and will be completed within one month of the conclusion of enrollment.

  2. Signal-to-Noise Ratio (SNR)

    Signal-to-noise will be measured from the blood pool in the aorta and main pulmonary artery and compared against myocardial signal for contrast-to-background calculations in contrast-enhanced MRA and 4D Flow signal images. This ca be readily performed by placing a region of interest (ROI) within the vessel of interest and calculating the standard deviation of signal intensities relative to mean signal intensity.

    Time frame: SNR will be assessed on a rolling basis during the study by the study team and will be completed within one month of the conclusion of enrollment.

  3. Standard Deviation of Volumetric Flow Measurements

    We will measure standard deviation of volumetric flow measurements from the aorta and main pulmonary artery from ROIs that are typically used in our clinical routine to measure systemic and pulmonary blood flow. The standard error in these measurements will be compared between each of the four randomized conditions.

    Time frame: Standard deviation of flow measurements will be assessed on a rolling basis during the study by all attending radiologists and will be completed within one month after the conclusion of enrollment.

07

Study locations

1 site
  • University of California San Diego Health
    San Diego, California 92037, United States
08

References and documents

Publications

  • Jacobs K, Hahn L, Horowitz M, Kligerman S, Vasanawala S, Hsiao A. Hemodynamic Assessment of Structural Heart Disease Using 4D Flow MRI: How We Do It. AJR Am J Roentgenol. 2021 Dec;217(6):1322-1332. doi: 10.2214/AJR.21.25978. Epub 2021 Jun 2. PubMed 34076463 ↗
  • Kebebew E, Tresler PA, Siperstein AE, Duh QY, Clark OH. Normal thyroid pathology in patients undergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literature. Thyroid. 1999 Feb;9(2):127-31. doi: 10.1089/thy.1999.9.127. PubMed 10090311 ↗
  • Hsiao A, Alley MT, Massaband P, Herfkens RJ, Chan FP, Vasanawala SS. Improved cardiovascular flow quantification with time-resolved volumetric phase-contrast MRI. Pediatr Radiol. 2011 Jun;41(6):711-20. doi: 10.1007/s00247-010-1932-z. Epub 2011 Jan 11. PubMed 21221566 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2024 to primary completion in Apr 2026, 20 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: start May 2024 → Aug 2024, primary completion Jun 2025 → Apr 2026 and completion Jun 2025 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2024
First posted
May 9, 2024
StartActual
Aug 5, 2024was May 2024
Primary completionActual
Apr 23, 2026was Jun 2025
CompletionActual
Aug 23, 2026was Jun 2025
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 3, 2026
Start date
May 2024→Aug 5, 2024 (actual)
Nov 3, 2026
Primary completion
Jun 2025→Apr 23, 2026 (actual)
Nov 3, 2026
Study completion
Jun 2025→Aug 23, 2026 (actual)
Nov 3, 2026
Enrollment
160 (estimated)→161 (actual)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Not yet recruiting→Completed
    Start date May 2024→Aug 5, 2024 (now actual)
    Primary completion Jun 2025→Apr 23, 2026 (now actual)
    Study completion Jun 2025→Aug 23, 2026 (now actual)
    Enrollment 160 (estimated)→161 (actual)
    + 6 other changes: verification date, oversight details, description, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06406517
Collaborators
Bracco Imaging S.p.A.
Responsible party
Albert Hsiao (Professor in Residence, University of California, San Diego) — Principal investigator
First posted
May 9, 2024
Start date
Aug 5, 2024
Primary completion
Apr 23, 2026
Completion
Aug 23, 2026
Last update
Nov 3, 2026

Study contacts

Albert Hsiao, MD/PhD
principal investigator · Department of Radiology, UC San Diego

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadopiclenol

Start the discussion